Overview

S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients

Status:
Completed

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effectiveness and safety of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

Taiho Pharmaceutical Co., Ltd.

Treatments:

Cisplatin
Oxaliplatin